Abstract
Anti-citrullinated protein/peptide antibodies (ACPA) are the principal autoantibody system associated with rheumatoid arthritis (RA), with diagnostic sensitivity of 70% and specificity of 95%. Current testing for ACPA uses the anti-cyclic citrullinated peptide assay (anti-CCP) which measures a generalized reactivity with citrulline-containing peptides, thus giving no insight into reactivity to specific RA antigens. Of these, the best characterized are, α-enolase, fibrinogen/fibrin, vimentin, Type 2 collagen and filaggrin, antibodies to each of which are found in approximately 30-60% of RA cases. Given reports of cross-reactivity between citrullinated antigens, we discuss whether or not measuring these specific antibodies could aid: clinical diagnosis, identification of clinical subsets and drug responses, or provide insight into pathogenic mechanisms or etiology of RA.
Original language | English |
---|---|
Pages (from-to) | 1185-92 |
Number of pages | 8 |
Journal | Expert Review of Clinical Immunology |
Volume | 9 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2013 |
Keywords
- Animals
- Arthritis, Rheumatoid
- Autoantibodies
- Autoantigens
- Biological Markers
- Biomarkers, Pharmacological
- Citrulline
- Cross Reactions
- Epitopes
- Humans
- Prognosis
- Sensitivity and Specificity
- Serology